Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial

Narges Alipanah-Lechner,James Hurst-Hopf,Kevin Delucchi,Lamorna Swigart,Andrew Willmore,Benjamin LaCombe,Robin Dewar,H. Clifford Lane,Perrine Lallemand,Kathleen D. Liu,Laura Esserman,Michael A. Matthay,Carolyn S. Calfee,Neil R. Aggarwal,Timothy Albertson,Sara Auld,Jeremy R. Beitler,Paul Berger,Ellen L. Burnham,Nathan Cobb,Alessio Crippa,Andrea Discacciati,Martin Eklund,D. Clark Files,Eliot Friedman,Sheetal Gandotra,Kashif Khan,Jonathan Koff,Santhi Kumar,Thomas R. Martin,Nuala J. Meyer,Timothy Obermiller,Philip Robinson,Derek Russell,Karl Thomas,Se Fum Wong,Richard G. Wunderink,Mark M. Wurfel,Albert Yen,Fady A. Youssef,Anita Darmanian,Amy L. Dzierba,Ivan Garcia,Katarzyna Gosek,Purnema Madahar,Aaron M. Mittel,Justin Muir,Amanda Rosen,John Schicchi,Alexis L. Serra,Romina Wahab,Kevin W. Gibbs,Leigha Landreth,Mary LaRose,Lisa Parks,Adina Wynn,Caroline A. G. Ittner,Nilam S. Mangalmurti,John P. Reilly,Donna Harris,Abhishek Methukupally,Siddharth Patel,Lindsie Boerger,John Kazianis,Carrie Higgins,Jeff McKeehan,Brian Daniel,Scott Fields,Alejandra Jauregui,Daniel Belvins,Catherine Nguyen,Alexis Suarez,Maged A. Tanios,Farjad Sarafian,Usman Shah,Max Adelman,Christina Creel-Bulos,Joshua Detelich,Gavin Harris,Katherine Nugent,Christina Spainhour,Philip Yang,Angela Haczku,Erin Hardy,Richart Harper,Brian Morrissey,Christian Sandrock,G. R. Scott Budinger,Helen K. Donnelly,Benjamin D. Singer,Ari Moskowitz,Melissa Coleman,Joseph Levitt,Ruixiao Lu,Paul Henderson,Adam Asare,Imogene Dunn,Alejandro Botello Barragan,the I-SPY COVID Consortium
DOI: https://doi.org/10.1186/s13054-024-04819-0
IF: 15.1
2024-02-24
Critical Care
Abstract:Despite evidence associating inflammatory biomarkers with worse outcomes in hospitalized adults with COVID-19, trials of immunomodulatory therapies have met with mixed results, likely due in part to biological heterogeneity of participants. Latent class analysis (LCA) of clinical and protein biomarker data has identified two subtypes of non-COVID acute respiratory distress syndrome (ARDS) with different clinical outcomes and treatment responses. We studied biological heterogeneity and clinical outcomes in a multi-institutional platform randomized controlled trial of adults with severe COVID-19 hypoxemic respiratory failure (I-SPY COVID).
critical care medicine
What problem does this paper attempt to address?